Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia (AML)

被引：7
|
作者：
Stone, Richard M. [1 ]
DeAngelo, Daniel J. [1 ]
Galinsky, Ilene [1 ]
Kokulis, Caroline [1 ]
Stewart, Jeremy M. [1 ]
McGinnis, Michael [1 ]
Werner, Lillian [2 ]
Letai, Anthony G. [1 ]
Konopleva, Marina Y. [3 ]
Luskin, Marlise [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124966
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3908
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA)
    Krauter, Juergen
    Fiedler, Walter
    Schlenk, Richard F.
    Paschka, Peter
    Thol, Felicitas
    Luebbert, Michael
    Wattad, Mohammad Amen
    Verbeek, Mareike
    Koenecke, Christian
    Neuhaus, Barbara
    Kebenko, Maxim
    Janning, Melanie
    Dohner, Konstanze
    Gaidzik, Verena I.
    Becker, Heiko
    Greil, Christine
    Reimer, Peter
    Goetze, Katharina
    Doehner, Hartmut
    Ganser, Arnold
    Heuser, Michael
    BLOOD, 2016, 128 (22)
  • [32] Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years: Cancer and Leukemia Group B (CALGB) Study 10502
    Attar, Eyal C.
    Donohue, Kathleen A.
    Amrein, Philip C.
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Kolitz, Jonathan E.
    Powell, Bayard L.
    Voorhees, Peter M.
    Wang, Eunice S.
    Blum, William
    Booth, Allison
    Stone, Richard M.
    Moser, Barry K.
    Larson, Richard
    BLOOD, 2010, 116 (21) : 150 - 150
  • [33] Comparison of Liposomal Daunorubicin and Cytarabine Versus Cladribine and High-Dose Cytarabine-Based Induction Chemotherapy in Secondary Acute Myeloid Leukemia Patients (sAML) or Acute Myeloid Leukemia with Myelodysplastic Related Changes (AML-MRC)
    Denson, Ariel
    Caddell, Ryan J.
    Richter, Katherine A.
    Li, Jiannong
    Sweet, Kendra
    Kuykendall, Andrew T.
    Padron, Eric
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    Talati, Chetasi
    Sallman, David A.
    BLOOD, 2021, 138
  • [34] Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)
    Wang, Amy
    Weiner, Howard
    Larson, Richard A.
    Odenike, Olatoyosi
    Artz, Andrew S.
    Bishop, Michael R.
    Godley, Lucy
    Thirman, Michael
    Kosuri, Satyajit
    Churpek, Jane
    Curran, Emily K.
    Pettit, Kristen
    Stock, Wendy
    Liu, Hongtao
    BLOOD, 2018, 132
  • [35] A PHASE 2 STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
    Cortes, J. E.
    Smith, B. D.
    Wang, E. S.
    Merchant, A.
    Oehler, V. G.
    Arellano, M.
    DeAngelo, D. J.
    Pollyea, D. A.
    Ma, W. W.
    Zeremski, M.
    Shaik, M. N.
    O'Connell, A.
    Chan, G.
    Schroeder, M. A.
    HAEMATOLOGICA, 2017, 102 : 50 - 50
  • [36] Combination of Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) Is Feasible and Tolerable
    Wang, Amy Y.
    Weiner, Howie Lawrence
    Green, Margaret
    Larson, Richard A.
    Odenike, Olatoyosi
    Artz, Andrew
    Godley, Lucy A.
    Thirman, Michael J.
    Churpek, Jane E.
    Curran, Emily K.
    Pettit, Kristen
    Stock, Wendy
    Liu, Hongtao
    BLOOD, 2016, 128 (22)
  • [37] Phase I study of a single high dose of liposomal daunorubicin combined with high dose cytarabine for adult patients with relapsed/refractory acute myelogenous leukemia (AML).
    Maslak, P
    Weiss, M
    Jurcic, J
    Cathcart, K
    Heaney, M
    Berman, E
    Soignet, S
    Scheinberg, D
    Ward, S
    BLOOD, 2000, 96 (11) : 325A - 325A
  • [38] Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study
    Gastaud, Lauris
    Peterlin, Pierre
    Hunault, Mathilde
    Raffoux, Emmanuel
    Bertoli, Sarah
    Carre, Martin
    Pautas, Cecile
    Chantepie, Sylvain
    Lambert, Juliette
    Duployez, Nicolas
    Celli-Lebras, Karine
    Mineur, Ariane
    Gardin, Claude
    Vey, Norbert
    Pigneux, Arnaud
    Delabesse, Eric
    Preudhomme, Claude
    Plesa, Adriana
    Vergez, Francois
    Hamel, Jean-Francois
    Dombret, Herve
    Recher, Christian
    BLOOD, 2023, 142
  • [39] Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia
    Zeidan, Amer Methqal
    Fathi, Amir Tahmasb
    Issa, Ghayas C.
    Erba, Harry Paul
    Ahsan, Julie
    Corum, Daniel
    Tomkinson, Blake E.
    Kozlek, Tom
    Leoni, Mollie
    Wang, Eunice S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Bouligny, Ian M.
    Kantarjian, Hagop M.
    Yilmaz, Musa
    Daver, Naval
    Borthakur, Gautam
    Dinardo, Courtney D.
    Montalban-Bravo, Guillermo
    Short, Nicholas J.
    Valero, Yesid Alvarado
    Jabbour, Elias
    Jain, Nitin
    Pemmaraju, Naveen
    Hammond, Danielle
    Chien, Kelly S.
    Takahashi, Koichi
    Issa, Ghayas C.
    Abbas, Hussein A.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2024, 144 : 735 - 736
12345